Search

Your search keyword '"Severs, Mirjam"' showing total 28 results
Start Over Author "Severs, Mirjam"
28 results on '"Severs, Mirjam"'

2. Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies

Author

Severs, Mirjam, Spekhorst, Lieke M, Mangen, Marie-Josée J, Dijkstra, Gerard, Löwenberg, Mark, Hoentjen, Frank, van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Bouma, Gerd, van der Woude, Janneke C, van der Valk, Mirthe E, Romberg-Camps, Marielle J L, Clemens, Cees H M, van de Meeberg, Paul, Mahmmod, Nofel, Jansen, Jeroen, Jharap, Bindia, Weersma, Rinse K, Oldenburg, Bas, Festen, Eleonora A M, and Fidder, Herma H

Published
2018
Full Text
View/download PDF

3. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease

Author

Severs, Mirjam, Mangen, Marie-Josée J., Fidder, Herma H., van der Valk, Mirthe E., van der Have, Mike, van Bodegraven, Ad A., Clemens, Cees H. M., Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J., Mahmmod, Nofel, van de Meeberg, Paul C., van der Meulen-de Jong, Andrea E., Pierik, Marieke, Ponsioen, Cyriel Y., Romberg-Camps, Marielle J. L., Siersema, Peter D., Jharap, Bindia, van der Woude, Janneke C., Zuithoff, Nicolaas P. A., and Oldenburg, Bas

Published
2017
Full Text
View/download PDF

5. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease

Author

UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Arts Assistenten Longziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), Severs, Mirjam, Mangen, Marie Josée J., Fidder, Herma H., Van Der Valk, Mirthe E., Van Der Have, Mike, Van Bodegraven, Ad A., Clemens, Cees H M, Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J, Mahmmod, Nofel, van de Meeberg, Paul C, Van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Romberg-Camps, Marielle J.L., Siersema, Peter D., Jharap, Bindia, van der Woude, C Janneke, Zuithoff, Nicolaas P.A., Oldenburg, Bas, UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Arts Assistenten Longziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), Severs, Mirjam, Mangen, Marie Josée J., Fidder, Herma H., Van Der Valk, Mirthe E., Van Der Have, Mike, Van Bodegraven, Ad A., Clemens, Cees H M, Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J, Mahmmod, Nofel, van de Meeberg, Paul C, Van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Romberg-Camps, Marielle J.L., Siersema, Peter D., Jharap, Bindia, van der Woude, C Janneke, Zuithoff, Nicolaas P.A., and Oldenburg, Bas

Published
2017

6. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up

Author

van der Valk, Mirthe E, Mangen, Marie-Josée J, Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, van de Meeberg, Paul C, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens, Vermeijden, J Reinoud, Siersema, Peter D, Leenders, Max, Oldenburg, Bas, COIN study group and the Dutch Initiative on Crohn and Colitis, van der Valk, Mirthe E, Mangen, Marie-Josée J, Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, van de Meeberg, Paul C, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens, Vermeijden, J Reinoud, Siersema, Peter D, Leenders, Max, Oldenburg, Bas, and COIN study group and the Dutch Initiative on Crohn and Colitis

Published
2016

8. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up

Author

HTA Onderzoek Team 1, JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, MS MDL 1, Cancer, Unit Opleiding Aios, Infection & Immunity, van der Valk, Mirthe E, Mangen, Marie-Josée J, Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, van de Meeberg, Paul C, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens, Vermeijden, J Reinoud, Siersema, Peter D, Leenders, Max, Oldenburg, Bas, COIN study group and the Dutch Initiative on Crohn and Colitis, HTA Onderzoek Team 1, JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, MS MDL 1, Cancer, Unit Opleiding Aios, Infection & Immunity, van der Valk, Mirthe E, Mangen, Marie-Josée J, Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, Jeroen M, van de Meeberg, Paul C, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens, Vermeijden, J Reinoud, Siersema, Peter D, Leenders, Max, Oldenburg, Bas, and COIN study group and the Dutch Initiative on Crohn and Colitis

Published
2016

9. Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease: A Comparison of Tools

Author

Cancer, Unit Opleiding Aios, Biostatistiek Onderzoek, Other research (not in main researchprogram), JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, HEE, MS MDL 1, Infection & Immunity, Severs, Mirjam, Zuithoff, Peter N P A, Mangen, Marie-Josée J, van der Valk, Mirthe E, Siersema, Peter D, Fidder, Herma H, Oldenburg, Bas, Cancer, Unit Opleiding Aios, Biostatistiek Onderzoek, Other research (not in main researchprogram), JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, HEE, MS MDL 1, Infection & Immunity, Severs, Mirjam, Zuithoff, Peter N P A, Mangen, Marie-Josée J, van der Valk, Mirthe E, Siersema, Peter D, Fidder, Herma H, and Oldenburg, Bas

Published
2016

11. Su1801 One Simple Question Is Sufficient for Measuring Medication Adherence in Inflammatory Bowel Disease Patients Using Self-Report

Author

Severs, Mirjam, primary, Mangen, Marie-Josée J., additional, Fidder, Herma H., additional, Van Der Valk, Mirthe E., additional, Van Der Have, Mike, additional, Van Bodegraven, Adriaan A., additional, Clemens, Cees H., additional, Dijkstra, Gerard, additional, Jeroen, M, additional, De Jong, Dirk J., additional, Mahmmod, Nofel, additional, van de Meeberg, Paul C., additional, Van Der Meulen, Andrea, additional, Pierik, Marie, additional, Ponsioen, Cyriel, additional, Romberg-Camps, Marielle, additional, Siersema, Peter D., additional, Vermeijden, Reinoud J., additional, Van Der Woude, Christien Janneke, additional, Zuithoff, Peter N., additional, and Oldenburg, Bas, additional

Published
2016
Full Text
View/download PDF

12. Sa1944 Non-Adherence to Medical Therapy Is Associated With Hospitalizations and the Development of Active Disease in Inflammatory Bowel Disease

Author

Severs, Mirjam, primary, Fidder, Herma H., additional, Mangen, Marie-Josée J., additional, van der Valk, Mirthe E., additional, van der Have, Mike, additional, van Bodegraven, Adriaan A., additional, Clemens, Cees H., additional, Dijkstra, Gerard, additional, Jeroen, M, additional, De Jong, Dirk J., additional, Mahmmod, Nofel, additional, van de Meeberg, Paul C., additional, van der Meulen, Andrea, additional, Pierik, Marie, additional, Ponsioen, Cyriel, additional, Romberg-Camps, Marielle, additional, Siersema, Peter D., additional, Vermeijden, Reinoud J., additional, van der Woude, Christien Janneke, additional, Zuithoff, Peter N., additional, and Oldenburg, Bas, additional

Published
2016
Full Text
View/download PDF

13. Sa1945 Lower Quality of Life, More Active Disease and Increased Healthcare Costs Due to Non-Adherence in Inflammatory Bowel Disease

Author

Severs, Mirjam, primary, Mangen, Marie-Josée J., additional, Fidder, Herma H., additional, van der Valk, Mirthe E., additional, van der Have, Mike, additional, van Bodegraven, Adriaan A., additional, Clemens, Cees H., additional, Dijkstra, Gerard, additional, Jeroen, M, additional, De Jong, Dirk J., additional, Mahmmod, Nofel, additional, van de Meeberg, Paul C., additional, van der Meulen, Andrea, additional, Pierik, Marie, additional, Ponsioen, Cyriel, additional, Romberg-Camps, Marielle, additional, Siersema, Peter D., additional, Vermeijden, Reinoud J., additional, van der Woude, Christien Janneke, additional, Zuithoff, Peter N., additional, and Oldenburg, Bas, additional

Published
2016
Full Text
View/download PDF

17. Self-reported Health Care Utilization of Patients with Inflammatory Bowel Disease Correlates Perfectly with Medical Records

Author

MS MDL 1, Cancer, Infection & Immunity, MS MDL Oncologie, HTA Onderzoek Team 1, JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, Severs, Mirjam, Petersen, Roosmarijn E., Siersema, Peter D., Mangen, Marie Josee J, Oldenburg, Bas, MS MDL 1, Cancer, Infection & Immunity, MS MDL Oncologie, HTA Onderzoek Team 1, JC onderzoeksprogramma Infectieziekten, Circulatory Health, JC onderzoeksprogramma Methodologie, Severs, Mirjam, Petersen, Roosmarijn E., Siersema, Peter D., Mangen, Marie Josee J, and Oldenburg, Bas

Published
2015

18. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission

Author

Unit Opleiding MDL, MS MDL 1, Cancer, Infection & Immunity, MS MDL Oncologie, Mooiweer, Erik, Severs, Mirjam, Schipper, Marguerite E I, Fidder, Herma H, Siersema, Peter D, Laheij, Robert J F, Oldenburg, Bas, Unit Opleiding MDL, MS MDL 1, Cancer, Infection & Immunity, MS MDL Oncologie, Mooiweer, Erik, Severs, Mirjam, Schipper, Marguerite E I, Fidder, Herma H, Siersema, Peter D, Laheij, Robert J F, and Oldenburg, Bas

Published
2015

19. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch–Anal Anastomosis, Ileostomy and Anti-TNFα Therapy

Author

van der Valk, Mirthe E., primary, Mangen, Marie-Josée J., additional, Severs, Mirjam, additional, van der Have, Mike, additional, Dijkstra, Gerard, additional, van Bodegraven, Ad A., additional, Fidder, Herma H., additional, de Jong, Dirk J., additional, Pierik, Marieke, additional, van der Woude, C. Janneke, additional, Romberg-Camps, Mariëlle J.L., additional, Clemens, Cees H.M., additional, Jansen, Jeroen M., additional, van de Meeberg, Paul C., additional, Mahmmod, Nofel, additional, van der Meulen-de Jong, Andrea E., additional, Ponsioen, Cyriel Y., additional, Bolwerk, Clemens, additional, Vermeijden, J. Reinoud, additional, Siersema, Peter D., additional, Leenders, Max, additional, and Oldenburg, Bas, additional

Published
2015
Full Text
View/download PDF

20. Su1300 Healthcare Expenditures for Inflammatory Bowel Disease Peak in Patients With a Short Disease Duration

Author

Severs, Mirjam, primary, van der Valk, Mirthe E., additional, Mangen, Marie-Josée Justine, additional, Have, Mike V., additional, Dijkstra, Gerard, additional, van Bodegraven, Adriaan A., additional, Fidder, Herma, additional, De Jong, Dirk J., additional, Pierik, Marie J., additional, van der Woude, Christien J., additional, Romberg-Camps, Mariëlle, additional, Clemens, Cees H., additional, Jansen, Jeroen M., additional, van de Meeberg, Paul C., additional, Mahmmod, Nofel, additional, van der Meulen - de Jong, Andrea E., additional, Ponsioen, Cyriel, additional, Bolwerk, Clemens, additional, Vermeijden, J.R., additional, Siersema, Peter D., additional, Leenders, Max, additional, and Oldenburg, Bas, additional

Published
2015
Full Text
View/download PDF

21. Tu1243 Evolution of IBD-Related Costs Over Two Years of Follow up: Increase of Anti-TNF α Therapy Related Costs With a Decline of Hospitalization Costs

Author

van der Valk, Mirthe E., primary, Mangen, Marie-Josée Justine, additional, Have, Mike V., additional, Severs, Mirjam, additional, Dijkstra, Gerard, additional, van Bodegraven, Adriaan A., additional, Fidder, Herma, additional, De Jong, Dirk J., additional, Pierik, Marie J., additional, van der Woude, Christien J., additional, Romberg-Camps, Mariëlle, additional, Clemens, Cees H., additional, Jansen, Jeroen M., additional, van de Meeberg, Paul C., additional, Mahmmod, Nofel, additional, van der Meulen - de Jong, Andrea E., additional, Ponsioen, Cyriel, additional, Bolwerk, Clemens, additional, Vermeijden, J.R., additional, Siersema, Peter D., additional, Leenders, Max, additional, and Oldenburg, Bas, additional

Published
2015
Full Text
View/download PDF

22. Su1299 Smoking Is Associated With Extra-Intestinal Manifestations in Inflammatory Bowel Disease

Author

Severs, Mirjam, primary, van Erp, Sanne JH, additional, Dijkstra, Gerard, additional, van der Valk, Mirthe E., additional, Mangen, Marie-Josée Justine, additional, Have, Mike V., additional, van Bodegraven, Adriaan A., additional, Fidder, Herma, additional, De Jong, Dirk J., additional, Pierik, Marie J., additional, van der Woude, Christien J., additional, Romberg-Camps, Mariëlle, additional, Clemens, Cees H., additional, Jansen, Jeroen M., additional, van de Meeberg, Paul C., additional, Mahmmod, Nofel, additional, Ponsioen, Cyriel, additional, Bolwerk, Clemens, additional, Vermeijden, J.R., additional, Siersema, Peter D., additional, Leenders, Max, additional, van der Meulen - de Jong, Andrea E., additional, and Oldenburg, Bas, additional

Published
2015
Full Text
View/download PDF

23. Sa1155 Smoking Is Associated With Higher Healthcare Costs in IBD Patients, Primarily Due to More Frequent Anti-TNFα Use

Author

Severs, Mirjam, primary, van der Valk, Mirthe E., additional, Mangen, Marie-Josée Justine, additional, Have, Mike V., additional, Dijkstra, Gerard, additional, van Bodegraven, Adriaan A., additional, Fidder, Herma, additional, De Jong, Dirk J., additional, Pierik, Marie J., additional, van der Woude, Christien J., additional, Romberg-Camps, Mariëlle, additional, Clemens, Cees H., additional, Jansen, Jeroen M., additional, van de Meeberg, Paul C., additional, Mahmmod, Nofel, additional, van der Meulen - de Jong, Andrea E., additional, Ponsioen, Cyriel, additional, Bolwerk, Clemens, additional, Vermeijden, J.R., additional, Siersema, Peter D., additional, Leenders, Max, additional, and Oldenburg, Bas, additional

Published
2015
Full Text
View/download PDF

26. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.

Author

van der Valk, Mirthe E., Mangen, Marie-Josée J., Severs, Mirjam, van der Have, Mike, Dijkstra, Gerard, van Bodegraven, Ad A., Fidder, Herma H., de Jong, Dirk J., van der Woude, C. Janneke, Romberg-Camps, Mariëlle J. L., Clemens, Cees H. M., Jansen, Jeroen M., van de Meeberg, Paul C., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., Bolwerk, Clemens, Vermeijden, J. Reinoud, Siersema, Peter D., and Leenders, Max

Subjects
INFLAMMATORY bowel disease treatment, HOSPITAL costs, TUMOR necrosis factors, CROHN'S disease, ULCERATIVE colitis, FOLLOW-up studies (Medicine)
Abstract

Background: With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up. Methods and Findings: In total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires. Changes of healthcare costs, productivity costs and out-of-pocket costs over time were assessed using mixed model analysis. Multivariable logistic regression analysis was used to identify costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable over two years of follow-up, with annual total costs of €7,835 in CD and €3,600 in UC. However, within healthcare costs, the proportion of anti-TNF therapy-related costs increased from 64% to 72% in CD (p<0.01) and from 31% to 39% in UC (p < 0.01). In contrast, the proportion of hospitalization costs decreased from 19% to 13% in CD (p<0.01), and 22% to 15% in UC (p < 0.01). Penetrating disease course predicted an increase of healthcare costs (adjusted odds ratio (adj. OR) 1.95 (95% CI 1.02–3.37) in CD and age <40 years in UC (adj. OR 4.72 (95% CI 1.61–13.86)). Conclusions: BD-related costs remained stable over two years. However, the proportion of anti-TNF-related healthcare costs increased, while hospitalization costs decreased. Factors associated with increased costs were penetrating disease course in CD and age <40 in UC. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

27. Paucity of gastrointestinal plasma cells in common variable immunodeficiency.

Author

Marsden JWN, Laclé MM, Severs M, and Leavis HL

Subjects
Humans, Immunoglobulin A immunology, Immunoglobulin A blood, Biopsy methods, Gastrointestinal Tract immunology, Gastrointestinal Tract pathology, Cell Count, Common Variable Immunodeficiency immunology, Common Variable Immunodeficiency diagnosis, Plasma Cells immunology
Abstract

Purpose of Review: Common variable immunodeficiency enteropathy (CVID-E) is a noninfectious complication of CVID caused by chronic inflammation of the gastrointestinal (GI) tract. Based on literature, a paucity or lack of plasma cells, although not obligatory for diagnosis, is a pathognomonic feature of CVID and more frequent in CVID-E. However, there is no consensus on standardized histopathological analysis of this feature in biopsies. In this systematic review, we highlight methods of reproducible plasma cell quantification of biopsies in CVID and describe the plasma cell counts and classes as presented in the literature., Recent Findings: Reduced plasma cell counts are commonly found over the entire GI tract, except for in the oesophagus. Immunoglobulin A+ (IgA+) plasma cells appear to be the most commonly reduced plasma cell class in CVID, yet there is scarce literature on the predictive value of low IgA+ plasma cell counts in CVID-E., Summary: We propose two optimized methodologies of quantification using a cut-of value of <10 plasma cells per HPF at 40× magnification, or a proportion of ≥1-5% of total mononuclear cells, recorded over ≥3 sections, and in ≥2 biopsies, as the most conservative agreeable definitions for a paucity of plasma cells to be used in diagnostics and further research., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

28. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

Author

Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, and Oldenburg B

Subjects
Adult, Biomarkers analysis, Colonoscopy, Disease Progression, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Inflammatory Bowel Diseases metabolism, Male, Middle Aged, ROC Curve, Recurrence, Retrospective Studies, Young Adult, Feces chemistry, Inflammatory Bowel Diseases diagnosis, Leukocyte L1 Antigen Complex analysis
Abstract

Background and Aims: Mucosal healing has become the treatment goal in patients with ulcerative colitis (UC) and Crohn's disease (CD). Whether low fecal calprotectin levels and histological healing combined with mucosal healing is associated with a further reduced risk of relapses is unknown., Methods: Patients with CD, UC or inflammatory bowel disease-unclassified (IBD-U) scheduled for surveillance colonoscopy collected a stool sample prior to bowel cleansing. Only patients with mucosal healing (MAYO endoscopic score of 0) were included. Fecal calprotectin was measured using a quantitative enzyme-linked immunosorbent assay (R-Biopharm, Germany). Biopsies were obtained from four colonic segments, and histological disease severity was assessed using the Geboes scoring system. Patients were followed until the last outpatient clinic visit or the development of a relapse, which was defined as IBD-related hospitalization, surgery or step-up in IBD medication., Results: Of the 164 patients undergoing surveillance colonoscopy, 92 patients were excluded due to active inflammation or missing biopsies. Of the remaining 72 patients (20 CD, 52 UC or IBD-U), six patients (8%) relapsed after a median follow-up of 11 months (range 5-15 months). Median fecal calprotectin levels at baseline were significantly higher for patients who relapsed compared with patients who maintained remission (284 mg/kg vs. 37 mg/kg. p < 0.01). Fecal calprotectin below 56 mg/kg was found to optimally predict absence of relapse during follow-up with 64% sensitivity, 100% specificity, 100% negative predictive value and 20% positive predictive value. The presence or absence of active inflammation determined by Geboes cut-off score of 3.1 was less strongly associated with the risk of relapse (64% sensitivity, 33% specificity, 9% negative predictive value and 92% positive predictive value., Conclusion: Low calprotectin levels identify IBD patients who remain in stable remission during follow-up., (Copyright © 2014 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results